Abstract | BACKGROUND: METHODS: RESULTS: Of 9006 enrolled and 7119 randomized patients in TWILIGHT, 1169 patients (13.0%) were enrolled at 27 Chinese sites in this prespecified substudy, of whom 1028 (14.4%) patients were randomized after 3 months. The incidence of the primary end point was 6.2% in the ticagrelor+aspirin group versus 3.5% in the ticagrelor+placebo group between randomization and 1 year (hazard ratio, 0.56 [95% CI, 0.31-0.99]; P=0.048). The key secondary end point occurred in 3.4% of patients in the ticagrelor+aspirin group versus 2.4% in the ticagrelor+placebo group (hazard ratio, 0.70 [95% CI, 0.33-1.46]; P=0.34). There was no interaction between the region of randomization (China versus the rest of the world) and randomized treatment assignment in terms of the primary or key secondary end points. CONCLUSIONS: REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02270242.
|
Authors | Yaling Han, Bimmer E Claessen, Shao-Liang Chen, Qiu Chunguang, Yujie Zhou, Yawei Xu, Lin Hailong, Jiyan Chen, Wu Qiang, Ruiyan Zhang, Suxin Luo, Yongjun Li, Jianhua Zhu, Xianxian Zhao, Xiang Cheng, Jian'an Wang, Xi Su, Jianhong Tao, Yingxian Sun, Geng Wang, Yi Li, Liya Bian, Ridhima Goel, Samantha Sartori, Zhongjie Zhang, Dominick J Angiolillo, David J Cohen, C Michael Gibson, Adnan Kastrati, Mitchell Krucoff, Shamir R Mehta, E Magnus Ohman, Philippe Gabriel Steg, Yuqi Liu, George Dangas, Samin Sharma, Usman Baber, Roxana Mehran |
Journal | Circulation. Cardiovascular interventions
(Circ Cardiovasc Interv)
Vol. 15
Issue 4
Pg. e009495
(04 2022)
ISSN: 1941-7632 [Electronic] United States |
PMID | 35317615
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Ticagrelor
- Aspirin
|
Topics |
- Aspirin
- Drug Therapy, Combination
- Hemorrhage
(etiology)
- Humans
- Percutaneous Coronary Intervention
(adverse effects)
- Platelet Aggregation Inhibitors
- Ticagrelor
(therapeutic use)
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|